Anorexia nervosa
Anorexia nervosa is a serious mental illness characterised by severe restriction of calorie intake and a preoccupation of body weight and shape.
Globally, about 2.2% of women and 0.3% of men suffer from anorexia nervosa at some point in their lives.1
An estimated one in five of people with anorexia nervosa do not recover or improve but go on to develop a long-term or chronic form of the condition.2
Anorexia nervosa also carries the highest mortality rate of all psychiatric disorders3. There is no approved pharmacological treatment option for those living with the illness.
About our anorexia nervosa study
We are conducting a phase 2 clinical trial investigating the efficacy and safety of investigational COMP360 psilocybin treatment in anorexia nervosa.
The study will recruit 60 participants and currently has trial sites in the US, UK, and Ireland.
For more information about the study, please click here.
Hear from the trial investigators…
Dr Walter Kaye, Professor of Psychiatry at the University of California San Diego School of Medicine, Department of Psychiatry Eating Disorders Program
Dr Kaye is leading the phase 2 clinical trial at the University of California San Diego School of Medicine. He also conducted an exploratory, open-label investigator-initiated study for anorexia nervosa in May 2022
Dr Hubertus Himmerich, Clinical Senior Lecturer in Eating Disorders at King’s College London and Consultant Psychiatrist at South London and Maudsley NHS Foundation Trust
Dr Himmerich is leading the phase 2 clinical trial at King’s College London.
